drugset / Trial / NCT00311844

A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)

NCT00311844

Phase 4 Completed 41 enrolled Organon and Co
RandomizedCrossoverDouble-blindTreatment

Summary

This study was a double-blind, placebo-controlled, cross-over, single-center study of desloratadine 5 mg or placebo in subjects 18 years of age or older with a history of seasonal allergic rhinoconjunctivitis. This study was performed to examine the effects of desloratadine compared with placebo, on the signs and symptoms of allergic conjunctivitis induced by direct conjunctival challenges with a previously identified sensitizing antigen, in the eyes of a subject known to be sensitive to the antigen.

Timeline

Start
2005-03-01
Primary completion
2005-05-28
Completion
2005-05-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Desloratadine Small molecule 5 mg Oral

Indications